Skip to main content

Clinical trial AMG510

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation

Organ Multiple
Trial status Trial open for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 1/2
Academic trial Non
Sponsor Amgen
EudraCT Identifier 2018-001400-11
Inclusion criteria Locally-advanced or metastatic malignancy with : KRAS p.G12Cmutation
Last update